About BCAL Diagnostics
BCAL Diagnostics Limited is an Australian biotechnology company dedicated to advancing early, non-invasive breast cancer diagnosis. For over a decade, we have been developing diagnostic technologies designed to complement mammograms and improve screening outcomes for women worldwide.
Our NATA-accredited commercial laboratory, equipped with advanced Liquid Chromatography Mass Spectrometry (LCMS) technology, is at the core of our scientific innovation and clinical service delivery – supporting both ongoing research and the commercial rollout of our diagnostic test.
Founded in 2010 and headquartered in Sydney, Australia, BCAL Diagnostics Limited is listed on the Australian Securities Exchange (ASX: BDX).
OUR VISION
BCAL Diagnostics aims to lead a global shift in breast cancer diagnosis by partnering with doctors to deliver non-invasive diagnostics that integrate seamlessly with clinical care
Our Values
Patient-Centred Innovation
We create accessible, non-invasive diagnostic tools that support informed decisions
Early Detection, Better Outcomes
We advanced R&D in breast cancer diagnostics to improve patient outcomes.
Partnerships for Progress
We collaborate with doctors, researchers, and investors to expand access and drive innovation.
Scientific & Clinical Excellence
We pursue rigorous research and validation to deliver trusted, high-impact diagnostic tools.
Integrity & Governance
We uphold transparency, accountability, and strong ethical standards across all areas of our business.
Sustainable Growth
We’re committed to responsible growth that delivers long-term value for patients, partners, investors and society.
Our Laboratories
Australia
Sydney, NSW: BCAL Diagnostics NATA-accredited commercial clinical laboratory is delivering its first-in-class blood test, BREASTEST plus™, to patients in consultation with healthcare professionals.
Equipped with cutting-edge Liquid Chromatography Mass Spectrometry (LCMS) technology, the facility supports ongoing clinical research, ensures robust diagnostic performance, and enables the scalable delivery of BCAL Diagnostics non-invasive breast test for breast cancer, BREASTEST plus™.
United States
Raleigh, North Carolina: In September 2024, BCAL Diagnostics expanded to the United States with a dedicated research and development site to accelerate product validation and enhance global accessibility.
Clinical studies and lab operations are now underway at partner blood collection sites in Michigan and Illinois, enabling BCAL Diagnostics to validate new products using US-based, patient data.
These efforts also provide key insights into the US diagnostics landscape. Early collaborations with physicians are active in both Michigan and Illinois.
For more information on how to support BCAL Diagnostics patient recruitment in the US, contact a member of the BCAL Diagnostics support team at [email protected].
Meet our Board of Directors
Meet Our TeamBCAL Diagnostic Limited highly experienced Board of Directors brings together proven expertise in biotechnology, diagnostics, healthcare innovation, and global business strategy. Backed by depth of knowledge in biomedical start-ups and the broader life sciences industry, they are committed to driving scientific excellence, clinical innovation, and global accessibility for BCAL’s breakthrough breast cancer screening technology.
